EVMN
EVOMMUNE (EVMN)
NYSE
$5.21+$0.04 (+0.70%)
Price as of Oct 22, 2026 7:30 PM EDT
  • $187.6M
    Market Cap
  • N/A
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
Income Statement
Total Operating Revenue
13.0M
N/A
Cost of Revenue
N/A
N/A
Gross Profit
13.0M
N/A
Sales and Marketing Expense
N/A
N/A
Research and Development Expense
-74.0M
N/A
Depreciation and Amortization Expense
1.4M
N/A
Total Operating Expenses
94.1M
N/A
Operating Profit
-81.1M
N/A
Interest Income
3.3M
N/A
Interest Expense
N/A
N/A
Interest Income and Expense and Net
3.3M
N/A
Total Nonoperating Income and Expense
12.2M
N/A
Income before Taxes
-68.9M
N/A
Income Taxes
0
N/A
Extraordinary Items
0
N/A
Net Income
-68.9M
N/A
Net Income from Continuing Operations Applicable to Common
-68.9M
N/A
Basic EPS and Net Income
-11.22
N/A
Diluted EPS and Net Income
-11.22
N/A
Basic Weighted Average Shares
6.1M
N/A
Diluted Weighted Average Shares
6.1M
N/A
Balance Sheet
Cash and Cash Equivalents
44.1M
N/A
Short-Term Investments
105.1M
N/A
Cash and Cash Equivalents and Short-Term Investments
149.2M
N/A
Total Current Assets
153.5M
N/A
Accumulated Depreciation
1.6M
N/A
Property and Plant and Equipment and Net
994,000
N/A
Total Long-Term Assets
101,000
N/A
Total Assets
224.9M
N/A
Income Taxes Payable
N/A
N/A
Total Short-Term Debt
N/A
N/A
Total Current Liabilities
17.9M
N/A
Total Long-Term Debt
N/A
N/A
Total Long-Term Liabilities
1.3M
N/A
Total Liabilities
19.4M
N/A
Retained Earnings
-221.1M
N/A
Total Stockholders Equity
205.6M
N/A
Total Shares Outstanding
31.5M
N/A
Cash Flow
Cash from Operating Activities
-76.4M
N/A
Capital Expenditures
235,000
N/A
Cash from Investing Activities
-115.3M
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
220.8M
N/A
Financials Ratio
Gross Margin
N/A
N/A
Operating Margin
N/A
N/A
Return on Assets
N/A
N/A
Return on Equity
N/A
N/A
Revenue Growth
N/A
N/A
Current Ratio
N/A
N/A
Cash Ratio
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow